Profile

Torsten Falk

Research Professor | Research Professor, Pharmacology | Member of the Graduate Faculty | Professor, Physiological Sciences - GIDP | Professor, Neuroscience - GIDP

Neurology

Courses(2)

Neuropharmacolgy
Principles of Cellular and Molecular Neurobiology

Student Thesis/Dissertation(9)

Preclinical Evaluation of the Mechanism Underlying Ketamine Activity as a Treatment for Parkinson's Disease and L-DOPA-Induced Dyskinesia
2024·doctoral
Evaluation of Systemically Delivered Glycopeptides for the Treatment of Acute Brain Injury and Parkinson's Disease
2024·doctoral
LITERATURE REVIEW: NEUROLOGICAL MECHANISMS THAT UNDERLIE THE THERAPEUTIC POTENTIAL OF THE DISSOCIATIVE COMPOUNDS: KETAMINE, PSILOCYBIN, LSD, AND DMT
2022·bachelors
FRIEDREICH’S ATAXIA: A RARE NEURODEGENERATIVE CONDITION
2021·bachelors
Modulation of Opioid and NMDA Receptors in Preclinical Models of Parkinson’s Disease and Levodopa-Induced Dyskinesia
2020·doctoral

Page 1 of 2

Technologies & Patents(4)

Compositions And Methods For Treating Motor Disorders
2022·Patent
Glycosylated PACAP/VIP Analogues with Enhanced CNS Penetration for Treatment of Neurodegenerative Diseases
2018·Patent
Glycopeptide and Classical Drug Design
2017·Technology
Glycosylated PACAP/VIP Analogues with Enhanced CNS Penetration for Treatment of Neurodegenerative Diseases
1899·Patent

News(8)

Page 1 of 2

Profile

Torsten Falk

Courses(2)

Neuropharmacolgy

Principles of Cellular and Molecular Neurobiology

Student Thesis/Dissertation(9)

Preclinical Evaluation of the Mechanism Underlying Ketamine Activity as a Treatment for Parkinson's Disease and L-DOPA-Induced Dyskinesia

Evaluation of Systemically Delivered Glycopeptides for the Treatment of Acute Brain Injury and Parkinson's Disease

LITERATURE REVIEW: NEUROLOGICAL MECHANISMS THAT UNDERLIE THE THERAPEUTIC POTENTIAL OF THE DISSOCIATIVE COMPOUNDS: KETAMINE, PSILOCYBIN, LSD, AND DMT

FRIEDREICH’S ATAXIA: A RARE NEURODEGENERATIVE CONDITION

Modulation of Opioid and NMDA Receptors in Preclinical Models of Parkinson’s Disease and Levodopa-Induced Dyskinesia

Technologies & Patents(4)

Compositions And Methods For Treating Motor Disorders

Glycosylated PACAP/VIP Analogues with Enhanced CNS Penetration for Treatment of Neurodegenerative Diseases

Glycopeptide and Classical Drug Design

Glycosylated PACAP/VIP Analogues with Enhanced CNS Penetration for Treatment of Neurodegenerative Diseases

News(8)

Following nature's rules, researchers develop new methods for treating degenerative neurological disease

Pharma Company Licenses UArizona Method for Treating Parkinson's Disease with Ketamine

Clinical Trial to Repurpose Ketamine for Parkinson’s Patients

UA Researchers Develop Brain-Mapping Technology

Blazing New Trails